PHIA Koninklijke Philips N.V.

Philips announces exchange ratio for 2019 dividend

Philips announces exchange ratio for 2019 dividend

July 6, 2020

Amsterdam, the Netherlands – (NYSE: PHG; AEX: PHIA) today announced that the exchange ratio for the dividend for the year 2019 has been determined. The exchange ratio is 1 new common share for every 49.2971 existing common shares. This ratio was based on the volume weighted average price on Euronext Amsterdam of June 30, and July 1 and 2, 2020, of EUR 41.8725 and was calculated in a manner that the gross dividend in shares will be approximately equal to EUR 0.85. As a result, Philips will issue a total number of 18,080,198 new common shares.

The dividend will be made payable to shareholders from July 7, 2020. Upon payment of the dividend, the total issued share capital will amount to EUR 182,210,600.20, representing 911,053,001 common shares. After deduction of treasury shares, the total number of outstanding shares will be 909,395,209 shares (2019: 909,194,188).

For further information, please contact:

Ben Zwirs

Philips Global Press Office

Tel.:

E-mail:

Derya Guzel

Philips Investor Relations

Tel.:

E-mail:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at .

Forward-looking statements

This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

 

EN
06/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Hoag selects Philips to enhance and unify patient monitoring, elevatin...

Hoag selects Philips to enhance and unify patient monitoring, elevating care across Orange County, USA October 30, 2025 10-year collaboration aims to connect scalable monitoring technology that streamlines workflows, supporting patient safety and the patient and clinician experienceAmsterdam, the Netherlands and Newport Beach, Calif., USA – (NYSE: PHG, AEX: PHIA), a global leader in health technology, and , Orange County, California’s highest-ranked hospital, today announced a landmark 10-year strategic collaboration. The initiative will standardize and modernize patient monitoring across...

 PRESS RELEASE

Late-breaking iMODERN findings presented at TCT 2025 and published in ...

Late-breaking iMODERN findings presented at TCT 2025 and published in the New England Journal of Medicine highlight new evidence to guide treatment choices for heart attack patients October 29, 2025 3-Year data from the largest global trial to date using Class I, Level A iFR in heart attack patients shows treating additional stenoses in the same procedure showed no significant difference in major outcomes compared with waiting for follow-upAdditional results from the ILIAS ANOCA study highlight the sustained benefits of physiology-guided assessment and tailored medical therapy for patients...

Oliver Metzger ... (+2)
  • Oliver Metzger
  • Wim Gille

ResearchPool Subscriptions

Get the most out of your insights

Get in touch